ArticleBritish journal of cancer2014

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

C L Schwab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.